interleukin 2

Summary

Summary: A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.

Top Publications

  1. ncbi Both integrated and differential regulation of components of the IL-2/IL-2 receptor system
    Hyoung Pyo Kim
    Laboratory of Molecular Immunology, Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1674, United States
    Cytokine Growth Factor Rev 17:349-66. 2006
  2. pmc Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
    Wanjun Chen
    Cellular Immunology Section, Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 198:1875-86. 2003
  3. ncbi Selective stimulation of T cell subsets with antibody-cytokine immune complexes
    Onur Boyman
    Department of Immunology, IMM4, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 311:1924-7. 2006
  4. ncbi Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
    S Sakaguchi
    Precursory Research for Embryonic Science and Technology PRESTO, Research and Development Corporation of Japan JRDC, Tsukuba Life Science Center
    J Immunol 155:1151-64. 1995
  5. ncbi IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells
    Matthew A Burchill
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    J Immunol 178:280-90. 2007
  6. ncbi The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 6:595-601. 2006
  7. pmc Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
    Matthew A Williams
    Howard Hughes Medical Institute and Department of Immunology, University of Washington, Seattle, Washington 98195, USA
    Nature 441:890-3. 2006
  8. pmc IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients
    Mojgan Ahmadzadeh
    Surgery Branch, NCI, NIH, Bethesda, MD 20892, USA
    Blood 107:2409-14. 2006
  9. ncbi Interleukin-2 is essential for CD4+CD25+ regulatory T cell function
    Maurus de la Rosa
    Deutsches Rheuma ForschungsZentrum Berlin, Berlin, Germany
    Eur J Immunol 34:2480-8. 2004
  10. ncbi Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation
    Arian Laurence
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 26:371-81. 2007

Research Grants

Detail Information

Publications351 found, 100 shown here

  1. ncbi Both integrated and differential regulation of components of the IL-2/IL-2 receptor system
    Hyoung Pyo Kim
    Laboratory of Molecular Immunology, Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1674, United States
    Cytokine Growth Factor Rev 17:349-66. 2006
    ..We now cover an under-reviewed area-the regulation of genes encoding IL-2 and IL-2R components, with an effort to integrate/explain this knowledge...
  2. pmc Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
    Wanjun Chen
    Cellular Immunology Section, Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 198:1875-86. 2003
    ..Finally, in a murine asthma model, coadministration of these TGF-beta-induced suppressor T cells prevented house dust mite-induced allergic pathogenesis in lungs...
  3. ncbi Selective stimulation of T cell subsets with antibody-cytokine immune complexes
    Onur Boyman
    Department of Immunology, IMM4, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 311:1924-7. 2006
    ..Thus, different cytokine-antibody complexes can be used to selectively boost or inhibit the immune response...
  4. ncbi Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
    S Sakaguchi
    Precursory Research for Embryonic Science and Technology PRESTO, Research and Development Corporation of Japan JRDC, Tsukuba Life Science Center
    J Immunol 155:1151-64. 1995
    ..Abnormality of this T cell-mediated mechanism of peripheral tolerance can be a possible cause of various autoimmune diseases...
  5. ncbi IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells
    Matthew A Burchill
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    J Immunol 178:280-90. 2007
    ..Finally, STAT5 binds to the promoter of the foxp3 gene suggesting that IL-2Rbeta-dependent STAT5 activation promotes Treg differentiation by regulating expression of foxp3...
  6. ncbi The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 6:595-601. 2006
    ..As discussed in this Review, the biology of these cytokines will affect the development of novel therapies for malignancy and autoimmune diseases, as well as the design of vaccines against infectious diseases...
  7. pmc Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
    Matthew A Williams
    Howard Hughes Medical Institute and Department of Immunology, University of Washington, Seattle, Washington 98195, USA
    Nature 441:890-3. 2006
    ..These results have important implications for the development of vaccination or immunotherapeutic strategies aimed at boosting memory T-cell function...
  8. pmc IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients
    Mojgan Ahmadzadeh
    Surgery Branch, NCI, NIH, Bethesda, MD 20892, USA
    Blood 107:2409-14. 2006
    ..Our findings suggest that selective inhibition of IL-2-mediated enhancement of regulatory T cells may improve the therapeutic effectiveness of IL-2 administration...
  9. ncbi Interleukin-2 is essential for CD4+CD25+ regulatory T cell function
    Maurus de la Rosa
    Deutsches Rheuma ForschungsZentrum Berlin, Berlin, Germany
    Eur J Immunol 34:2480-8. 2004
    ..We propose the parakrine uptake of soluble mediators as a flexible mechanism to adapt Treg activity to the strength of the responder T cell reaction...
  10. ncbi Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation
    Arian Laurence
    Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 26:371-81. 2007
    ..We conclude that in addition to the promotion of activation-induced cell death of lymphocytes and the generation of Treg cells, inhibition of Th17 polarization appears to be an important function of IL-2...
  11. pmc Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:5941-6. 2006
    ..This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity...
  12. pmc Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load
    Kerry A Millington
    Tuberculosis Immunology Group, Department of Respiratory Medicine, National Heart and Lung Institute, Wright Fleming Institute of Infection and Immunity, Imperial College London, London, United Kingdom
    J Immunol 178:5217-26. 2007
    ..These distinct T cell functional signatures before and after treatment suggest a novel immunological marker of mycobacterial load and clinical status in tuberculosis that now requires validation in larger prospective studies...
  13. ncbi Inducible IL-2 production by dendritic cells revealed by global gene expression analysis
    F Granucci
    University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, Milan, Italy
    Nat Immunol 2:882-8. 2001
    ..Approximately 3000 differentially expressed transcripts were identified. We found that functional interleukin 2 (IL-2) mRNA, which gave rise to IL-2 production, was transiently up-regulated at early time-points after ..
  14. ncbi CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2
    Thomas R Malek
    Department of Microbiology and Immunology, University of Miami School of Medicine, FL 33101, USA
    Immunity 17:167-78. 2002
    ..These observations indicate that the essential function of the IL-2/IL-2R system primarily lies at the level of the production of CD4(+)CD25(+) regulatory T cells...
  15. pmc HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
    R T Davey
    National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 96:15109-14. 1999
    ..Virologic relapse occurs rapidly in patients who discontinue suppressive drug therapy, even in patients with a markedly diminished pool of resting, latently infected CD4(+) T cells...
  16. pmc Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression
    Wei Liao
    Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 9:1288-96. 2008
    ..Our results identify a previously unappreciated function for IL-2 in 'priming' T cells for T(H)2 differentiation and in maintaining the expression of Il4ra and other genes in T(H)2-committed cells...
  17. pmc Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
    P S Linsley
    Oncogen Division, Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 91821
    J Exp Med 173:721-30. 1991
    ..Stimulation of T cells with B7+ CHO cells also specifically increased levels of interleukin 2 transcripts...
  18. ncbi Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?
    Maria A Curotto de Lafaille
    Molecular Pathogenesis Program, Kimmel Center for Biology and Medicine of the Skirball Institute, and Department of Pathology, New York University School of Medicine, 540 First Avenue, New York, NY 10016, USA
    Immunity 30:626-35. 2009
    ....
  19. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  20. ncbi A function for interleukin 2 in Foxp3-expressing regulatory T cells
    Jason D Fontenot
    Howard Hughes Medical Institute, Department of Immunology, University of Washington, Seattle, Washington 98195, USA
    Nat Immunol 6:1142-51. 2005
    ..Most T(reg) cells constitutively express the high-affinity interleukin 2 (IL-2) receptor alpha-chain (CD25); however, the precise function of IL-2 in T(reg) cell biology has remained ..
  21. ncbi Inducing and expanding regulatory T cell populations by foreign antigen
    Karsten Kretschmer
    Department of Pathology, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nat Immunol 6:1219-27. 2005
    ..The addition of transforming growth factor-beta or the absence of interleukin 2 production, which reduces proliferation, enhanced the conversion rate...
  22. ncbi Protein kinase C(theta) in T cell activation
    Noah Isakov
    Department of Microbiology and Immunology, Faculty of Health Sciences, and the Cancer Research Center, Ben Gurion University of the Negev, Beer Sheva 84105, Israel
    Annu Rev Immunol 20:761-94. 2002
    ..The selective expression of PKC theta in T cells and its essential role in mature T cell activation establish it as an attractive drug target for immunosuppression in transplantation and autoimmune diseases...
  23. ncbi Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor
    K H Grabstein
    Immunex Research and Development Corporation, Seattle, WA 98101
    Science 264:965-8. 1994
    ..Monoclonal antibodies to the beta chain of the IL-2 receptor inhibited the biological activity of IL-15, and IL-15 competed for binding with IL-2, indicating that IL-15 uses components of the IL-2 receptor...
  24. ncbi Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma
    Yukihiko Kato
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 13:4538-46. 2007
    High-dose interleukin 2 (IL-2) is a Food and Drug Administration-approved regimen for patients with metastatic renal cell carcinoma. However, the toxicity and limited clinical benefit associated with IL-2 has hampered its use...
  25. ncbi The expanding universe of T-cell subsets: Th1, Th2 and more
    T R Mosmann
    Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada
    Immunol Today 17:138-46. 1996
    ....
  26. ncbi Immune responses in interleukin-2-deficient mice
    T M Kundig
    Institute of Experimental Immunology, University of Zurich, Switzerland
    Science 262:1059-61. 1993
    ..Natural killer cell activity was markedly reduced but inducible. These normal in vivo immune responses in IL-2-deficient mice question the importance of IL-2 as defined by in vitro studies...
  27. pmc Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
    H Jonuleit
    Department of Dermatology, University of Mainz, D 55101 Mainz, Germany
    J Exp Med 192:1213-22. 2000
    ..These data show that immature and mature DCs induce different types of T cell responses: inflammatory Th1 cells are induced by mature DCs, and IL-10-producing T cell regulatory 1-like cells by immature DCs...
  28. pmc Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC Room 3 3940, 10 Center Drive, MSC 1201, Bethesda, MD 20814, USA
    Ann Surg Oncol 12:1005-16. 2005
    ..In this study, we assessed the antitumor activity and autoimmune toxicity of CTLA-4 blockade in combination with an immune-activating stimulus, interleukin (IL)-2, in patients with metastatic melanoma...
  29. ncbi FOXP3 controls regulatory T cell function through cooperation with NFAT
    Yongqing Wu
    Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 80309, USA
    Cell 126:375-87. 2006
    ..Thus by switching transcriptional partners, NFAT converts the acute T cell activation program into the suppressor program of Tregs...
  30. pmc Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
    Qizhi Tang
    Department of Surgery, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143 0540, USA
    Immunity 28:687-97. 2008
    ..Together, these results suggest intra-islet Treg cell dysfunction secondary to defective IL-2 production is a root cause of the progressive breakdown of self-tolerance and the development of diabetes in nonobese diabetic mice...
  31. ncbi A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory
    Christine Bourgeois
    INSERM U345, Institut Necker, 156 rue de Vaugirard, F 75730 Paris Cedex 15, France
    Science 297:2060-3. 2002
    ..These results suggest that, like B cells, CD8+ T cells receive CD4 help directly through CD40 and that this interaction is fundamental for CD8+ T cell memory generation...
  32. pmc A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory
    Akiko Murayama
    Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba Science City, Ibaraki, Japan
    EMBO J 25:1081-92. 2006
    ..Our observations indicate that Oct-1-binding followed by CpG demethylation are key events in the epigenetic regulation of IL2 expression and may act as a memory of the regulatory event...
  33. pmc Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization
    Ruka Setoguchi
    Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606 8507, Japan
    J Exp Med 201:723-35. 2005
    ..Furthermore, impairment of this negative feedback loop via IL-2 can be a cause and a predisposing factor for autoimmune disease...
  34. ncbi Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells
    D J Fowell
    Department of Medicine, University of California San Francisco 94143, USA
    Immunity 11:399-409. 1999
    ..Development of protective Th1 cells was unimpeded. These data define a nonredundant role for Itk in modulating signals from the TCR/CD28 pathways that are specific for the establishment of stable IL-4 but not IFNgamma expression...
  35. pmc Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype
    Dat Q Tran
    Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:2983-90. 2007
    ..These results suggest that even high levels of FOXP3 expression are insufficient to define a human CD4+ T cell as a T-regulatory cell...
  36. ncbi Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers
    Afonso R M Almeida
    Lymphocyte Population Biology, Unité de Recherche Associée Centre National de la Recherche Scientifique 1961, Institut Pasteur, Paris, France
    J Immunol 169:4850-60. 2002
    ....
  37. pmc IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
    Emmanuel Zorn
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:1571-9. 2006
    ..Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo...
  38. ncbi Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process
    Denis Bruniquel
    Laboratory of Cellular and Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0420, USA
    Nat Immunol 4:235-40. 2003
    ..These results imply that this demethylation process proceeds by an active enzymatic mechanism...
  39. ncbi Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells
    R Moriggl
    Howard Hughes Medical Institute, and Department of Biochemistry, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Immunity 10:249-59. 1999
    ..These phenotypes are not seen in mice lacking Stat5a or Stat5b alone. The results demonstrate that the Stat5 proteins, redundantly, are essential mediators of IL-2 signaling in T cells...
  40. pmc IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508
    Eun Sook Hwang
    Division of Molecular Life Sciences and College of Pharmacy, Ewha Womans University, Seoul, Korea
    J Exp Med 202:1289-300. 2005
    ..Heterodimerization of T-bet and RelA interferes with the binding of RelA to the IL-2 promoter, and hence, transcriptional activation of the IL-2 gene by RelA...
  41. pmc Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype
    Alexandre Harari
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1011 Lausanne, Switzerland
    Proc Natl Acad Sci U S A 104:16233-8. 2007
    ..These results provide the rationale for the observed protective role of HLA-B in HIV-1-infection and new insights into the relationship between TCR avidity, PD-1 expression, and the functional profile of CD8 T cells...
  42. pmc Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients
    Thomas Schwaab
    Medical Oncology Immunotherapy Group, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Clin Cancer Res 15:4986-92. 2009
    ..To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-alpha 2a in metastatic renal cell carcinoma patients...
  43. ncbi A distal region in the interferon-gamma gene is a site of epigenetic remodeling and transcriptional regulation by interleukin-2
    Jay H Bream
    Lymphocyte and Cell Biology Section, Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892 1820, USA
    J Biol Chem 279:41249-57. 2004
    ..These data led us to conclude that this distal region serves as both a target of chromatin remodeling in the IFNG locus as well as an IL-2-induced transcriptional enhancer that binds Stat5 proteins...
  44. pmc Interleukin-2 receptor signaling in regulatory T cell development and homeostasis
    Matthew A Burchill
    Center for Immunology, The Cancer Center, Department of Laboratory Medicine and Pathology, University of Minnesota, 312 Church Street SE, 6 116 Nils Hasselmo Hall, Minneapolis, MN 55455, USA
    Immunol Lett 114:1-8. 2007
    ....
  45. ncbi A novel NF-kappaB binding site controls human granzyme B gene transcription
    Chunjian Huang
    Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, China
    J Immunol 176:4173-81. 2006
    ..Our data also demonstrate that this binding site is functional in Jurkat T cells. Taken together, we identified a novel NF-kappaB binding site, which plays a pivotal role in controlling human granzyme B gene transcription...
  46. ncbi CD4+CD25high regulatory cells in human peripheral blood
    C Baecher-Allan
    Laboratory of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115
    J Immunol 167:1245-53. 2001
    ....
  47. ncbi IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells
    Steven J Burgess
    Receptor Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol 176:1490-7. 2006
    ..These data indicate that IL-21 is able to channel NK and CD8+ T cell function by altering the expression pattern of activation/costimulatory receptors...
  48. ncbi Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P
    Angel V Delgado
    Laboratory Support Branch, US Army Institute of Surgical Research, Fort Sam Houston, TX 78234, USA
    Neuropeptides 37:355-61. 2003
    ..study, we show the effect of Substance P on the production of Tumor Necrosis Factor-alpha, Interleukin 1-beta, Interleukin 2, and Interleukin 6 by T-lymphocytes, macrophages and neutrophils...
  49. ncbi Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production
    Sarah E Allan
    Department of Surgery, University of British Columbia, and Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute, 2660 Oak Street, Vancouver, Canada
    Int Immunol 19:345-54. 2007
    ..These data indicate that our current understanding of how FOXP3 contributes to immune tolerance in humans needs to be re-evaluated...
  50. ncbi Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection
    Haijun Zhou
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, China
    Gut 59:1699-708. 2010
    ..This study evaluated the prognostic values of intratumoral and peritumoral Th1/Th2 cytokine protein levels in patients with HCC after curative resection...
  51. ncbi Mechanisms of suppression by suppressor T cells
    Harald von Boehmer
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Immunol 6:338-44. 2005
    ....
  52. ncbi CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor
    Rebecca S McHugh
    Cellular Immunology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 16:311-23. 2002
    ..Importantly, antibodies to GITR abrogated suppression, demonstrating a functional role for this receptor in regulating the CD4(+)CD25(+) T cell subset...
  53. pmc Interleukin 2 plays a central role in Th2 differentiation
    Javier Cote-Sierra
    Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:3880-5. 2004
    ..Thus, IL-2 plays a critical role in the polarization of naive CD4 T cells to the Th2 phenotype...
  54. ncbi Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
    Gabriella Pietra
    Dipartimento di Medicina Sperimentale and Centro di Eccellenza per la Ricerca Biomedica, Universita degli Studi di Genova, Genova, Italy
    Int Immunol 21:793-801. 2009
    ..Since CSC have been reported to be both drug resistant and radioresistant, our present data suggest that NK-based adoptive immunotherapy could represent a novel therapeutic approach to possibly eradicate metastatic melanoma...
  55. ncbi A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation
    Toru Koike
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, CA 2004, 1120 15th Street, Augusta, GA 30912 2600, USA
    J Biol Chem 278:15685-92. 2003
    ..Together, the data demonstrate the presence of a novel activation process following TCR stimulation that requires ERK-dependent regulation of c-Rel, a member of the NF-kappaB family...
  56. pmc Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor
    J G Giri
    Immunex Research and Development Corporation, Seattle, WA 98101, USA
    EMBO J 14:3654-63. 1995
    ..IL-15R alpha is structurally similar to IL-2R alpha; together they define a new cytokine receptor family. The distribution of IL-15 and IL-15R alpha mRNA suggests that IL-15 may have biological activities distinct from IL-2...
  57. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
    ....
  58. ncbi Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    A Löffler
    Department of Haematology, Oncology and Tumourimmunology, Robert Rossle Clinic, Charite, Humboldt University of Berlin, Berlin, Germany
    Leukemia 17:900-9. 2003
    ..Although anti-CD95 antibody CH-11 failed to induce apoptosis in lymphoma cells, we provide evidence that B-CLL cell depletion by bscCD3 x CD3 is mediated at least in part by apoptosis via the caspase pathway...
  59. pmc Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes
    J Zhang
    Department of Medicine, University of Toronto, Ontario, Canada M5G 1X5
    J Exp Med 190:1329-42. 1999
    ..The data also reveal a role for WASp in modulating endocytosis and phagocytosis and, accordingly, suggest that the immune deficit conferred by WASp deficiency reflects the disruption of a broad range of cellular behaviors...
  60. ncbi A cloned chicken lymphokine homologous to both mammalian IL-2 and IL-15
    R S Sundick
    Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    J Immunol 159:720-5. 1997
    ..It has one characteristic that is unique to IL-15: four conserved cysteines allowing for two intrachain disulfide bonds...
  61. ncbi Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation
    Yixin Jin
    Department of Anatomy and Physiology, Institute of Basic Medical Sciences, University of Oslo, Norway
    Blood 101:4909-15. 2003
    ..Further, S1P or DHS1P but not ceramide or sphingosine enhanced rather than decreased secretion of interleukin 2 and interferon gamma by T cells stimulated with anti-CD3 plus anti-CD28...
  62. ncbi Identification and distribution of the costimulatory receptor CD28 in the mouse
    J A Gross
    Department of Molecular and Cell Biology, University of California, Berkeley 94720
    J Immunol 149:380-8. 1992
    ..The potent costimulatory function of CD28 on mature T cells, together with the high level of expression on CD4+8+ thymocytes, suggest that this costimulatory receptor might play an important role in T cell development and activation...
  63. ncbi CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ
    S Radoja
    Department of Cell Biology and Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016, USA
    J Immunol 166:6074-83. 2001
    ..Our data demonstrate that TIL, not tumor, express both Fas and FasL, are arrested in G(1), do not secrete cytokine in situ, and, upon activation in vitro and in vivo, rapidly die by activation-induced cell death...
  64. pmc High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease
    Peter K C Goon
    Department of Immunology, Imperial College London, London W2 1PG, United Kingdom
    J Virol 77:9716-22. 2003
    ..The data suggest that HTLV-1-specific CD4(+) T cells play a role in the pathogenesis of HAM/TSP...
  65. pmc Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells
    Adam D Judge
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Exp Med 196:935-46. 2002
    ..Thus, subsets of memory-phenotype T cells differ radically in their sensitivity to IL-15...
  66. ncbi Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment
    Lee Kim Swee
    Departement Biomedizin Basel, University of Basel, Switzerland
    Blood 113:6277-87. 2009
    ..It also reinforces the relevance of FLT3L treatment in GVHD by its ability to increase both the number of tolerizing DCs and NTregs...
  67. ncbi Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting
    H Schorle
    Institute of Virology and Immunobiology, University of Wurzburg, Germany
    Nature 352:621-4. 1991
    ....
  68. ncbi Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)
    T M Jourdier
    Département recherche et développement, Aventis Pasteur, Campus Merieux, 1541 Avenue Marcel Merieux, Marcy l Etoile, France
    Gene Ther 10:2126-32. 2003
    ....
  69. pmc Reciprocal activating interaction between natural killer cells and dendritic cells
    Franca Gerosa
    Department of Pathology, Section of Immunology, University of Verona, 37100 Verona, Italy
    J Exp Med 195:327-33. 2002
    ..These data demonstrated for the first time a bidirectional cross talk between NK cells and DC, in which NK cells activated by IL-2 or by mature DC induce DC maturation...
  70. ncbi Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: subset-specific differences in IL-2 regulation
    Mary A Yui
    Division of Biology 156 29, California Institute of Technology, Pasadena, CA 91125, USA
    J Immunol 172:4691-9. 2004
    ....
  71. pmc Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin
    Laura Strauss
    Department of Pathology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 4:e5994. 2009
    ..Here, we studied expansion, IL-2R-gamma chain signaling, survival pathways and resistance to apoptosis in human Treg responding to RAPA...
  72. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  73. pmc Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells
    Hans Dooms
    Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA
    J Exp Med 204:547-57. 2007
    ..These results identify IL-2 as a factor regulating IL-7Ralpha expression and, consequently, memory T cell homeostasis in vivo...
  74. ncbi Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression
    F Kontgen
    Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria, Australia
    Genes Dev 9:1965-77. 1995
    ..The ability of exogenous interleukin-2 to restore T Cell, but not B cell, proliferation indicates that Rel regulates the expression of different genes in B and T cells that are crucial for cell division and immune function...
  75. ncbi NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
    Per A Albertsson
    Department of Oncology, Sahlgrenska University Hospital, S 41345, Goteborg, Sweden
    Trends Immunol 24:603-9. 2003
    ..New insights into the migration of NK cells, their activation status and production of matrix-degrading proteases might help to overcome this localization defect, with implications for the treatment of human cancer...
  76. ncbi BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
    Norihiko Watanabe
    Department of Pathology and Immunology, Howard Hughes Medical Institute, Washington University School of Medicine, Box 8118, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nat Immunol 4:670-9. 2003
    ..homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2)...
  77. ncbi The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements
    H P Kim
    Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 15:159-72. 2001
    ..Thus, the IL-2 inducibility of the IL-2Ralpha gene is unexpectedly mediated by two widely separated regulatory Stat5-dependent elements, located both upstream and downstream of the transcription initiation sites...
  78. pmc In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells
    X Wang
    David H. Smith Center for Vaccine Biology and Immunology, Aab Institute for Biomedical Sciences, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Exp Med 194:1069-80. 2001
    ....
  79. ncbi Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells
    D Tzachanis
    Department of Adult Oncology, Dana Farber Cancer Institute, Division of Medical Oncology, Harvard Medical School, Boston, MA 02115, USA
    Nat Immunol 2:1174-82. 2001
    ..Tob associated with Smad2 and Smad4 and enhanced Smad DNA-binding. The inhibitory effect of Tob on interleukin 2 (IL-2) transcription was not mediated by blockade of NFAT, AP-1 or NF-kappaB transactivation but by ..
  80. ncbi The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice
    Calliope A Dendrou
    Juvenile Diabetes Research Foundation Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke s Hospital, Cambridge, CB2 OXY, UK
    J Clin Immunol 28:685-96. 2008
    ....
  81. ncbi An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans
    Anders Wikby
    Department of Natural Science and Biomedicine, School of Health Sciences, Jonkoping University, Sweden
    J Gerontol A Biol Sci Med Sci 60:556-65. 2005
    ..b>Interleukin 2 responsiveness to concanavalin A, using data from the previous OCTO (octogenarians) immune study, hereafter ..
  82. ncbi Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice
    Evridiki Sgouroudis
    Department of Microbiology and Immunology, and McGill Center for the Study of Host Resistance, McGill University, Montreal, Quebec, Canada
    J Immunol 181:6283-92. 2008
    ....
  83. ncbi Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB
    E Ayroldi
    Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Perugia, Via del Giochetto, 06100 Perugia, Italy
    Blood 98:743-53. 2001
    ..These results identify a new molecular mechanism involved in the dexamethasone-induced regulation of NF-kappaB activity and T-cell activation. (Blood. 2001;98:743-753)..
  84. ncbi Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2
    J A Johnston
    Leukocyte Cell Biology Section, PRI DynCorp, Frederick, Maryland
    Nature 370:151-3. 1994
    ..Here we report that a new member of the Janus family of kinases (Jak-3) is coupled to the IL-2R in human peripheral blood T cells and natural killer cells...
  85. ncbi Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy
    L Capuron
    Institut National de la Santé et de la Recherche Médicale U 394, Neurobiologie Integrative, Institut Francois Magendie, and Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France
    J Clin Oncol 18:2143-51. 2000
    ..The objective of the present study was to evaluate the depressive and anxiety symptoms induced by IL-2 and/or INFalpha-2b in cancer patients during the first days of cytokine immunotherapy...
  86. ncbi Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections
    Martin F Bachmann
    Cytos Biotechnology AG, Zurich Schlieren, Switzerland
    Eur J Immunol 37:1502-12. 2007
    ..Thus, depending on the chronicity of antigen exposure, IL-2R signaling is either essential or largely dispensable for induction and maintenance of virus-specific CD8+ T cell responses...
  87. pmc Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells
    Stefan Stangl
    Department of Radiotherapy Radiooncology, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaningerstrasse 22, Munich, Germany
    Cell Stress Chaperones 13:221-30. 2008
    ..These findings indicate that Hsp70 (as an activatory molecule) and HLA-E (as an inhibitory ligand) expression influence the susceptibility of leukemic cells to the cytolytic activities of cytokine/TKD-activated NK cells...
  88. ncbi Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling
    Louise M D'Cruz
    Research Institute of Molecular Pathology, 1030 Vienna, Austria
    Nat Immunol 6:1152-9. 2005
    b>Interleukin 2 signaling is believed to be critically involved in several aspects of CD25(+) CD4(+) regulatory T cell biology, such as intrathymic development, peripheral survival and suppressive function...
  89. ncbi The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines
    Julie M Roda
    Integrated Biomedical Sciences Graduate Program, Arthur G James Comprehensive Cancer Center and Solove Research Institute, Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 13:6419-28. 2007
    ..Cetuximab is a therapeutic monoclonal antibody directed against the HER1 antigen. We hypothesized that the NK cell response to cetuximab-coated tumor cells could be enhanced by the administration of NK cell-stimulatory cytokines...
  90. ncbi IL-27 limits IL-2 production during Th1 differentiation
    Alejandro V Villarino
    Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104, USA
    J Immunol 176:237-47. 2006
    ....
  91. ncbi A new protein containing an SH2 domain that inhibits JAK kinases
    T A Endo
    Institute of Life Science, Kurume University, Aikawamachi, Japan
    Nature 387:921-4. 1997
    ..JAB and CIS appear to function as negative regulators in the JAK signalling pathway...
  92. ncbi Differential roles for Wiskott-Aldrich syndrome protein in immune synapse formation and IL-2 production
    Judy L Cannon
    Committee on Immunology, University of Chicago, Chicago, IL 60637, USA
    J Immunol 173:1658-62. 2004
    ..Defects in IL-2 production are observed even under conditions in which immune synapse formation proceeds normally, suggesting that the role of WASP in regulating IL-2 production is independent of its role in immune synapse formation...
  93. pmc CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy
    Lequn Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Rm Mayer 547, Boston, MA 02115, USA
    Blood 106:3068-73. 2005
    ....
  94. ncbi Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma
    Junming Xian
    Department of Otolaryngology, West China Hospital, Chengdu
    Arch Otolaryngol Head Neck Surg 131:1079-85. 2005
    ....
  95. ncbi Overview of interleukin-2 function, production and clinical applications
    Sarah L Gaffen
    University at Buffalo, State University of New York, Department of Oral Biology and Department of Microbiology, 3435 Main Street, Buffalo, NY 14214, USA
    Cytokine 28:109-23. 2004
    ..Despite the wealth of information generated about IL-2 from in vitro culture systems, in vivo mouse knockout models, and clinical trials in humans, fascinating new aspects of its functions in the immune system continue to emerge...
  96. ncbi The role of Stat5a and Stat5b in signaling by IL-2 family cytokines
    J X Lin
    Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bldg 10 Rm 7N252, 9000 Rockville Pike, Bethesda, Maryland MD 20892 1674, USA
    Oncogene 19:2566-76. 2000
    ..Oncogene (2000)...
  97. ncbi Characterisation and expression analysis of interleukin 2 (IL-2) and IL-21 homologues in the Japanese pufferfish, Fugu rubripes, following their discovery by synteny
    Steve Bird
    Scottish Fish Immunology Research Centre, School of Biological Sciences, University of Aberdeen, Aberdeen AB24 2TZ, UK
    Immunogenetics 56:909-23. 2005
    This investigation provides the first conclusive evidence for the existence of the interleukin 2 (IL-2) and IL-21 genes in bony fish...
  98. pmc Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2
    J C Becker
    Department of Dermatology, University of Wurzburg, Germany
    Br J Cancer 87:840-5. 2002
    ..subsequent to a three week resting period, patients received an immunotherapy consisting of subcutaneous interleukin 2 and interferon alpha(2)...
  99. ncbi Molecular cloning and evolution of the gene encoding the precursor of Nilgai (Boselaphus tragocamelus) interleukin 2
    Dhanjit Kumar Das
    Indian Veterinary Research Institute, Centre for Wildlife, Izatnagar 243 122, UP, India
    DNA Seq 17:465-70. 2006
    b>Interleukin 2 is a key immunoregulatory cytokine that is involved in T helper differentiation and is known to induce interferon gamma (IFN-gamma) in natural killer (NK) and T-cell...
  100. ncbi Differential regulation of T-cell growth by IL-2 and IL-15
    Georgina H Cornish
    Cancer Research UK, London, England
    Blood 108:600-8. 2006
    Although interleukin 2 (IL-2) and IL-15 signal through the common gamma chain (gammac) and through IL-2 receptor beta-chain (CD122) subunits, they direct distinct physiologic and immunotherapeutic responses in T cells...
  101. pmc Large-scale expansion of rat CD4+ CD25+ T(reg) cells in the absence of T-cell receptor stimulation
    Niklas Beyersdorf
    University of Wurzburg, Institute for Virology and Immunobiology, Wurzburg, Germany
    Immunology 119:441-50. 2006
    ....

Research Grants80

  1. Neuroimaging abnormalities in major depressive disorder: effect of inflammation
    Jonathan Savitz; Fiscal Year: 2013
    ....
  2. Regulation of Innate and Adaptive Immunity in Human COPD and Emphysema
    Farrah Kheradmand; Fiscal Year: 2012
    ..is enriched with T helper type 1 (Th1) cells, CD4+ and CD8+ T lymphocytes that secrete cytokines such as interleukin 2 (IL-2), and interferon gamma (IFN-g)...
  3. Immune modulators of inflammation in servere COPD
    Farrah Kheradmand; Fiscal Year: 2010
    ..is enriched with T helper type 1 (Th1) cells, CD4+ and CD8+ T lymphocytes that secrete cytokines such as interleukin 2 (IL-2), and interferon gamma (IFN?)...
  4. Gene Transcription in SLE
    George C Tsokos; Fiscal Year: 2012
    ..SLE T cells produced reduced amounts of interleukin 2 (IL-2) which contributes to the increased rate of infections, decreased generation of cytotoxic and regulatory ..
  5. Nebraska/Kansas Blood and Marrow Transplant Research Network
    JULIE MARIE VOSE; Fiscal Year: 2013
    ..The BMT/CTN including our consortium will be the only clinical cooperative group to accomplish this goal. ..
  6. Antibody cytokine fusion proteins against Cryptococcus neoformans
    DAVID OWEN BEENHOUWER; Fiscal Year: 2012
    ..The proposed studies have relevance beyond cryptococcal infection, since a significant long-term objective is to design antibody-cytokine fusion proteins for use in other types of infections. ..
  7. HCV in Alcoholics
    Jack R Wands; Fiscal Year: 2011
    ..These investigations open new avenues to enhance antiviral immune response in the setting of chronic ethanol consumption by improving DC function. ..
  8. Pathophysiology of Adult T-cell Leukemia/Lymphoma
    UTPAL P DAVE; Fiscal Year: 2013
    ..Our aims are well-timed and can have a significant impact on a disease that is universally fatal upon diagnosis and advance our understanding of JAK3's role in T-cell neoplasia. ..
  9. Early Environmental Hygiene and Pediatric Asthma
    Christine C Johnson; Fiscal Year: 2009
    ..If factors associated with animal or endotoxin contact are related to asthma risk, such factors would likely lend themselves to public health interventions. ..
  10. Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity
    Manuel L Penichet; Fiscal Year: 2013
    ..A novel nanobiopolymer-based therapy against HER2/neu expressing cancer cells with sufficient capacity to inhibit angiogenesis and orchestrate an anti-tumor immune response should make a significant clinical impact. ..
  11. Type 1 Diabetes Mouse Resource (T1DR)
    David V Serreze; Fiscal Year: 2012
    ..The mission of the T1DR is to import, re-derive to a high-level health status, curate, genotypically and phenotypically validate, cryopreserve, and distribute mouse stocks of value to the T1D research community. ..
  12. New Strategies to Prevent Death from Influenza
    Kendall A Smith; Fiscal Year: 2010
    ..If successful, this research effort will provide the foundation for the development of a universal approach to the prevention and treatment of one of the world's most dangerous microbes, one that kills hundreds of thousands yearly. ..
  13. T1D:Investigating the Gut Microbiome, Urinary Proteome and Metabolome
    Ramana Madupu; Fiscal Year: 2011
    ..We propose to study the complex interplay of environmental, immunological and genetic factors to discover molecular signatures with a potential to advance clinical diagnosis and therapy at or before the onset of T1D. ..
  14. Efficacy and safety of novel CD80 IL15 IL15Ra expressing autologous AML vaccines
    KARIN L GAENSLER; Fiscal Year: 2013
    ..Studies will directly inform the design of a Phase 1 clinical AML vaccine trial at UCSF for patients >60, ineligible for HSCT. ..
  15. Signal transduction and gene induction in lymphocytes
    Anjana Rao; Fiscal Year: 2013
    ....
  16. Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease
    Jamie L Renbarger; Fiscal Year: 2013
    ..Ultimately, we propose the discovery of a GVHD-specific drug to increase efficacy and lower toxicity. ..
  17. Genetic Basis for susceptibility to EAE
    Vijay K Kuchroo; Fiscal Year: 2011
    ..abstract_text> ..
  18. The Role of EOS in Regulatory T-cell Biology.
    Drew M Pardoll; Fiscal Year: 2013
    ....
  19. Manipulation of Immune Responsiveness after Hematopoietic Cell Transplantation
    ROBERT JON SOIFFER; Fiscal Year: 2013
    ..PROJECT/PERFORMANGE SITE(S) (if additional space is needed, use Project/Perfonnance Site Fonnat Page) ..
  20. MOLECULAR AND CELLULAR ANALYSIS OF G PROTEIN FUNCTION
    Catherine H Berlot; Fiscal Year: 2013
    ..the small molecule, 1 gallein, leads to increased T cell receptor (TCR)-stimulated production of the cytokine, interleukin 2 (IL-2) in CD4+ T cells...
  21. The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy
    Paul M Sondel; Fiscal Year: 2013
    ....
  22. VEGI-192 As An Anticancer Therapeutic Agent
    LUYUAN LI; Fiscal Year: 2010
    ....
  23. Interleukin-2 and autoimmune disease
    Abul K Abbas; Fiscal Year: 2012
    ..These studies will shed light on the mechanisms of immune regulation and tolerance, and may help to optimize protocols for the therapeutic uses of IL-2 and its antagonists. ..
  24. Is Aberrant MO Stimulation Pivotal in Post-Trauma MODS?
    Carol L Miller-Graziano; Fiscal Year: 2012
    ....
  25. Mechanisms of invariant NKT cell-mediated in vivo anti-tumor responses
    Hamid Bassiri; Fiscal Year: 2013
    ..abstract_text> ..
  26. Bifunctional T cell receptor based immunotherapeutics
    Hing C Wong; Fiscal Year: 2011
    ..This may lead to a safe and effective approach to treat patients with refractory, metastatic cancer. ..
  27. Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
    Hyung L Kim; Fiscal Year: 2013
    ..abstract_text> ..
  28. MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
    CRAIG LEE SLINGLUFF; Fiscal Year: 2013
    ....
  29. Role of Tat and SIRT1 in the T-cell Hyperactivation Syndrome Induced by HIV-1
    MELANIE MARIA OTT; Fiscal Year: 2013
    ..These studies are directly relevant to HIV/AIDS and may contribute to the development of novel antiviral drugs that will address public need. ..
  30. Targeting Novel T Cell Antigens on Renal Cell Carcinoma
    Scott S Tykodi; Fiscal Year: 2010
    ..Identifying the key components of the tumor-specific immune response that occurs after such transplants may foster the development of novel and more effective immune therapies for this cancer. ..
  31. Targeting CaMK4 in SLE
    George C Tsokos; Fiscal Year: 2013
    ..The significance of the proposed work lies with the fact that it presents a novel target for the treatment of SLE and that it develops a targeted delivery of a small drug. ..
  32. THC impairment of CD4/CD8 T cell-mediated host resistance to HIV and influenza
    Norbert E Kaminski; Fiscal Year: 2013
    ....
  33. Naive T cell homeostasis: Treg selection and survival
    Christophe O Benoist; Fiscal Year: 2013
    ..The results should lead to a better understanding of this population that is key to immune and autoimmune regulation. ..
  34. Interferon actions and autoimmune disorders
    Michael David; Fiscal Year: 2010
    ..b>Interleukin 2 (IL-2) is powerful mitogen for T cells, and its production is a hallmark of T cell activation...
  35. TIM molecules and the innate: adaptive interface in alloimmunity
    Nader Najafian; Fiscal Year: 2013
    ..abstract_text> ..
  36. IL-2 scintigraphy as a guide to cancer immunotherapy
    SVETOMIR NENAD MARKOVIC; Fiscal Year: 2013
    ....
  37. Role of MEK1 in T cell function in asthma
    Rafeul Alam; Fiscal Year: 2013
    ..The proposal is important because it addresses the mechanism of persistence of airway inflammation in asthma. The results of this study will lead to the development of novel therapeutic modalities for asthma. ..
  38. Characterization of a novel T cell activating protein in arthritis
    Raphael Hirsch; Fiscal Year: 2013
    ..Characterization of FSTL-1 will advance understanding of arthritis and may provide new treatment options. ..
  39. MOLECULAR ENGINEERING OF IL-2 FOR THE TREATMENT AND PREVENTION OF TYPE I DIABETES
    AARON MICHAEL RING; Fiscal Year: 2013
    ..Thus, through these multidisciplinary and translational studies, we will advance new candidate T1D therapies for clinical development. ! ..
  40. Development of Intestinal Immune Regulation in Human Infants
    JOERN HENDRIK WEITKAMP; Fiscal Year: 2013
    ..This proposal develops novel translational approaches to identify cellular and molecular targets for reducing the pathologic host immune response in NEC and to detect infants at highest risk of this devastating disease. ..
  41. Enhancing renal cell carcinoma response to IL-2 with the HDAC inhibitor SNDX-275
    Roberto Pili; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): High dose interleukin 2 (IL-2) is an approved regimen for metastatic renal cell carcinoma (RCC). Unfortunately, the response rate is modest and only few patients achieve durable remission...
  42. Inflammation Pathways in Breast Cancer
    Margaret M Madeleine; Fiscal Year: 2010
    ..Cytokine genes are expressed at different levels in older compared to younger women;therefore, we will also evaluate their contribution to breast cancer risk by levels of common exposures such as obesity and HRT use. ..
  43. Genetic and Functional Analysis of IL-2 Deficiency in Lupus-Prone Mice
    Zhiwei Xu; Fiscal Year: 2013
    ..Our design of this project aims at identifying the gene responsible for the IL-2 deficiency and elucidating its roles in lupus pathogenesis, which will contribute to discovering a new therapeutic target for lupus treatment. ..
  44. Sphingosine Phosphate Role in Inflammation
    Lina Obeid; Fiscal Year: 2009
    ..These studies will enable us to gain important insight into the role of this pathway in inflammatory responses and may also provide novel therapeutic approaches to inflammation. ..
  45. Gene Transcription in SLE
    George C Tsokos; Fiscal Year: 2013
    ....
  46. GUT-DERIVED IMMUNE EFFECTOR CELLS
    John R Klein; Fiscal Year: 2012
    ..These studies will use in vitro approaches and in vivo gene therapy strategies to explore the involvement of Roquin, under the influence of IL-10, in the control of colonic IL-17 expression. ..
  47. Structure Function Studies of the Spindle-Pole Body in Saccharomyces Cerevisiae
    Ivan Rayment; Fiscal Year: 2012
    ..The fundamental knowledge gained here will be of great value in understanding the molecular basis of disease. ..
  48. Phase 1 Study of Interleukin-2 in Wiskott-Aldrich Syndrome
    Soma Jyonouchi; Fiscal Year: 2013
    ....
  49. Effects of diacylglycerol kinase zeta deficiency on CD8+ T cell function
    Matthew J Riese; Fiscal Year: 2013
    ..We have found a new target for treating cancer, dgk-zeta, which awakens the immune system in mice, preventing cancer growth. This grant will figure out exactly how dgk-zeta works in a type of T cell known to attack cancer cells. ..
  50. Enhancing Treg Immune Reconstitution After Stem Cell Transplant
    CATHERINE MARY BOLLARD; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): We propose using ultra low dose Interleukin 2 (ULD-IL2) to reduce the risk of Graft versus host disease after allogeneic hematopoietic stem cell transplantation (Allo SCT) by increasing levels of ..
  51. Phosphatases in Human Lupus
    George C Tsokos; Fiscal Year: 2013
    ....
  52. TGFbeta Blockade in MART TCR-Engineered T Cell Melanoma Immunotherapy in Man
    Richard C Koya; Fiscal Year: 2013
    ..This present proposal will directly address this problem with the goal of achieving sustained clinical responses. ..
  53. COSTIMULATORY SIGNALS IN CD4+ T CELL ACTIVATION
    MARC KEVIN JENKINS; Fiscal Year: 2013
    ..abstract_text> ..
  54. Cyclin-dependent kinases: Novel switches in anergy and targets for tolerance
    Andrew D Wells; Fiscal Year: 2012
    ....
  55. Regulatory T Cell-Deficient Mouse Model Rapidly Develops Sjogren's Syndrome
    Shyr Te Ju; Fiscal Year: 2010
    ..This study should identify new and useful models for Sjogren's syndrome research. It should identify new mechanism(s) for the pathogenesis of the disease and provide potential treatment of the disease. ..
  56. CHARACTERIZATION OF RECENT THYMIC EMIGRANTS
    Pamela J Fink; Fiscal Year: 2013
    ..The overall goal of these studies is to understand the biology of RTEs, a key but under-studied population of peripheral T cells. ..
  57. AIDS Lentivirus-induced TGF-beta+ Treg cells Mediate T cell Immune Dysfunction
    Mary B Tompkins; Fiscal Year: 2012
    ..Understanding how HIV co-opts this normal immune regulatory mechanism, which will be addressed in this proposal, will aid in the development of better therapeutic modalities. ..
  58. STRUCTURAL STUDIES OF A T CELL SPECIFIC TYROSINE KINASE
    Amy H Andreotti; Fiscal Year: 2013
    ..Kinases in particular are prime therapeutic targets since they control much of immune cell signaling and genetic defects in specific kinases are linked to specific human diseases. ..
  59. Arginine Availability, Modulated by MDSC, Regulates T Cell Function in Cancer
    Augusto C Ochoa; Fiscal Year: 2013
    ..Cancer vaccines and cytokines can be an important therapeutic approach for patients whose tumors have failed standard forms of treatment. ..
  60. Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses
    Padmanee Sharma; Fiscal Year: 2013
    ....
  61. NFAT/AP-1 cooperation in SLE T cells
    VASILEIOS CHRISTOS KYTTARIS; Fiscal Year: 2012
    ..In conclusion, the results of these studies will help us better understand how the SLE T cells respond to stimulation, identify potential targets for therapy and molecules that can be used as biomarkers. ..
  62. GENETIC ANALYSIS OF T CELLS IN LUPUS
    Joseph Craft; Fiscal Year: 2010
    ..Delineation of the pathways that are required for the development and maintenance of systemic autoimmunity will ultimately help foster better understanding of T-B cell collaboration as a therapeutic target in SLE. ..
  63. 1,25 DIHYDROXY VITAMIN D3 AND CELLULAR IMMUNITY
    Stavros Manolagas; Fiscal Year: 1991
    ....
  64. RENAL CELL CARCINOMA--ADOPTIVE IMMUNOTHERAPY
    KURT STENZEL; Fiscal Year: 1990
    ..Methodology and feasibility for on-line activation of lymphoid cells for adoptive immunotherapy will be investigated using a murine tumor model...
  65. EFFECTS OF PHORBOL ESTERS ON LYMPHOCYTE STIMULATION
    Andrea Mastro; Fiscal Year: 1991
    ..Mitogenic lectins along with macro-phages induce production of interleukin 1 (IL1), interleukin 2 (IL2), and their receptors which interact to cause proliferation. These interactions are not well understood...
  66. SIGNAL TRANSDUCTION IN T CELLS
    CONSTANTINE TSOUKAS; Fiscal Year: 1991
    ..We'll measure the effects of these agents on IP3 and Ca++ accumulation using a permeabilized cell system and electroporation...
  67. Soluble TCR-IL15 Fusions as Targeted Therapeutics for Cancer
    Peter Rhode; Fiscal Year: 2009
    ..Ultimately, this approach may provide a safer and more effective treatment for patients with cancer than the currently approved immunotherapies. ..
  68. PROTEINS BINDING TO THE HUMAN GAMMA INTERFERON PROMOTER
    Don Diamond; Fiscal Year: 1992
    ..The discovery that HTLV gene products modify the action of Cs A on the immune system has potential implication for patients in need of immunosuppressive therapy (transplantation) who have attendant retroviral- associated (HTLV) disease...
  69. CHRONOBIOLOGICAL INVESTIGATION OF TNF AND IL-2
    William Hrushesky; Fiscal Year: 1992
    ..biologic activities and anticancer activities of recombinant human Tumor Necrosis Factor (rhTNF) and Interleukin 2 (rhIL-2) in the Balb/c mouse with and without an implanted Meth-A sarcoma...
  70. ETOH A COFACTOR IN AIDS--MODULATION OF TH1 AND TH2 CELLS
    Shirish Barve; Fiscal Year: 1999
    ..In mice, EtOH causes depletion and oxidative stress sensitive transcription factors NF-kB and AP-1, in the development and/or activation of Th1 and Th2 responses in normal and MAIDS infected mice. ..
  71. MONOKINES IN CONTROL OF HYPOTHALAMIC-PUTUITARY AXIS
    Samuel McCann; Fiscal Year: 1991
    ..We will determine effects of interleukin 1 and interleukin 2 in altering hypothalamic pituitary function and determine whether the effects are mediated directly on the ..
  72. IMMUNOREGULATION OF ERYTHROPOIESIS
    Lee Levitt; Fiscal Year: 1992
    ..These studies should provide new information in the biology of hematopoietic immunoregulation and are relevant to our understanding of T cell membrane biology and T cell activation...
  73. Phase I Study of ALT-801 in Metastatic Melanoma/Kidney Cancer Patients
    Mayer Fishman; Fiscal Year: 2009
    ....
  74. DNA DAMAGE AS PREDICTOR OF CLINICAL RESPONSE IN MELANOMA
    Francis Ali Osman; Fiscal Year: 1999
    ..He will also facilitate the rational extension of biochemotherapy regimens to other more common solid tumors which traditionally are not treated with this modality. ..
  75. Naive T cell homeostasis: Treg selection and survival
    Christophe Benoist; Fiscal Year: 2009
    ..The results should lead to a better understanding of this population that is key to immune and autoimmune regulation. ..
  76. GRANULOMATOUS INFLAMMATION AND INTERLEUKIN-2
    Daniel Remick; Fiscal Year: 1990
    b>Interleukin 2 (IL-2) production and expression of its membrane- bound receptor (IL-2R) are critical steps in the T-cell activation and clonal expansion that occurs in delayed-type hypersensitivity (DTH) reactions...
  77. GUT FLORA AS A PROVOCATEUR OF AUTOIMMUNE COLITIS
    Peter Felsburg; Fiscal Year: 2002
    ..In addition, the ability of pathogenic T cells to cause or promote tissue injury through the production of toxic or inflammatory cytokines will also be investigated. ..
  78. Chemoimmunoprevention of prostate and breast cancer
    Enrico Mihich; Fiscal Year: 2004
    ..doses has immunomodulating effects that can be exploited in cooperation with prolonged treatments with interleukin 2 (IL2) at low doses in inducing cures of EL4 lymphoma and E0771 breast adenocarcinoma in syngeneic C57BL/6 mice...
  79. CANCER CHEMOTHERAPY AND IMMUNOLOGIC EFFECTS
    Enrico Mihich; Fiscal Year: 2001
    As shown in this laboratory, combinations of doxorubicin plus interleukin 2 (DOX + IL2) exert curative effects in C57BL/6 mice implanted with 10-5 EL4 lymphoma cells, a relatively nonimmunogenic syngeneic tumor/mouse model where 10 EL4 ..
  80. IL2 RECEPTORS--ANALYSIS OF ASSEMBLY AND SIGNALING
    Warner Greene; Fiscal Year: 1999
    ....